Renal Cell Carcinoma

Oncology
46
Pipeline Programs
28
Companies
50
Clinical Trials
7 recruiting
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
16
1
18
1
6
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1053%
Monoclonal Antibody
737%
Cell Therapy
15%
Vaccine
15%
+ 34 programs with unclassified modality

On Market (4)

Approved therapies currently available

E
LENVIMAApproved
lenvatinib
Eisai
Kinase Inhibitor [EPC]oral2015
Bayer
NEXAVARApproved
sorafenib
Bayer
Kinase Inhibitor [EPC]oral2005
Bristol Myers Squibb
OPDIVOApproved
nivolumab
Bristol Myers Squibb
injection2015
Pfizer
ZIRABEVApproved
bevacizumab-bvzr
Pfizer
Vascular Endothelial Growth Factor Inhibitor [EPC]injection2019

Competitive Landscape

26 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
8 programs
3
1
1
1
ZIRABEV(Bevacizumab)Phase 3Monoclonal Antibody5 trials
Axitinib plus ToripalimabPhase 2Monoclonal Antibody1 trial
AxitinibPhase 1Small Molecule1 trial
SGN-75Phase 11 trial
SGN-CD70APhase 11 trial
+3 more programs
Active Trials
NCT02776644Completed1,349Est. Dec 2017
NCT04555603Withdrawn0Est. Feb 2021
NCT01339962Completed1,073Est. Apr 2012
+9 more trials
Bristol Myers Squibb
7 programs
3
3
1
Infliximab + PrednisonePhase 21 trial
Neoadjuvant nivolumabPhase 2Monoclonal Antibody1 trial
OPDIVO(Opdivo)Phase 22 trials
BMS-936558Phase 11 trial
BMS-986506Phase 11 trial
+2 more programs
Active Trials
NCT03663946Completed81Est. May 2020
NCT01358721Completed119Est. May 2019
NCT07195682Recruiting125Est. Apr 2031
+5 more trials
E
EisaiChina - Liaoning
5 programs
1
3
1
1
LenvatinibPhase 3Small Molecule1 trial
DecitabinePhase 21 trial
PembrolizumabPhase 2Monoclonal Antibody1 trial
lenvatinibPhase 2Small Molecule1 trial
LenvatinibPhase 1Small Molecule1 trial
Active Trials
NCT03324373Completed11Est. Aug 2024
NCT00561912Terminated2Est. Nov 2009
NCT04704219Completed160Est. Oct 2025
+2 more trials
Bayer
BayerLEVERKUSEN, Germany
3 programs
2
1
1
sorafenibPhase 3Small Molecule1 trial
LeukinePhase 21 trial
SorafenibPhase 2Small Molecule1 trial
Active Trials
NCT00176280Withdrawn0
NCT00480389Completed19Est. Mar 2013
NCT00478114Completed15Est. Mar 2010
Nektar Therapeutics
Nektar TherapeuticsSAN FRANCISCO, CA
2 programs
1
1
bempegaldesleukinPhase 3
NivolumabPhase 1Monoclonal Antibody
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
2 programs
2
124-Iodine-cG250Phase 31 trial
IodinePhase 31 trial
Active Trials
NCT00606632Completed226Est. Dec 2009
NCT01762592Withdrawn0Est. Dec 2019
AB
Active BiotechSweden - Lund
1 program
1
ABR-217620/naptumomab estafenatoxPhase 2/31 trial
Active Trials
NCT00420888CompletedEst. Jan 2013
Astellas
AstellasChina - Shenyang
2 programs
1
1
CP-461Phase 21 trial
AGS-16M8FPhase 11 trial
Active Trials
NCT01114230Completed26Est. Nov 2012
NCT00036036Completed14Est. Jul 2003
CT
1 program
1
AnlotinibPhase 2Small Molecule1 trial
Active Trials
NCT02072044UnknownEst. Dec 2017
Arcus Biosciences
1 program
1
CasdatifanPhase 21 trial
Active Trials
NCT07397611Not Yet RecruitingEst. Sep 2029
Lantheus Medical Imaging
1 program
1
DefinityPhase 21 trial
Active Trials
NCT01062178CompletedEst. Dec 2012
IB
Immatics BiotechnologiesGermany - Munich
1 program
1
Endoxana, IMA901, LeukinePhase 21 trial
Active Trials
NCT00523159Completed68Est. Aug 2009
Genentech
GenentechCA - Oceanside
1 program
1
Erlotinib hydrochloridePhase 21 trial
Active Trials
NCT00353301Completed25Est. Mar 2012
Providence Therapeutics
1 program
1
High Dose IL-2Phase 21 trial
Active Trials
NCT02306954Active Not RecruitingEst. Dec 2026
Moderna
ModernaCAMBRIDGE, MA
1 program
1
Intismeran autogenePhase 21 trial
Active Trials
NCT06307431Active Not Recruiting272Est. Jun 2032
Abbott
AbbottABBOTT PARK, IL
1 program
1
VolociximabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT00100685Terminated48Est. Dec 2007
Sanofi
SanofiPARIS, France
1 program
1
Electrofusion DC vaccinePhase 1/2Vaccine1 trial
Active Trials
NCT00625755Completed40Est. Feb 2008
M&
Merck & Co.RAHWAY, NJ
3 programs
1
DS-6000aPhase 1
Decision aidN/A1 trial
avelumabN/AMonoclonal Antibody1 trial
Active Trials
NCT05548621Recruiting180Est. Dec 2025
NCT05650164Completed171Est. Oct 2023
Precision BioSciences
1 program
1
CD70 CAR-T cellsPhase 1Cell Therapy1 trial
Active Trials
NCT06010875Recruiting48Est. Sep 2026
CRISPR Therapeutics
1 program
1
CTX130Phase 11 trial
Active Trials
NCT04438083Terminated19Est. Oct 2024
DS
Daiichi SankyoChina - Shanghai
1 program
1
DS-6000aPhase 11 trial
Active Trials
NCT04707248Active Not Recruiting179Est. Jun 2026
HiFiBiO Therapeutics
HiFiBiO TherapeuticsMA - Cambridge
1 program
1
HFB200603Phase 11 trial
Active Trials
NCT05789069Active Not RecruitingEst. Dec 2025
Biotest Pharmaceuticals
Biotest PharmaceuticalsGermany - Dreieich
1 program
1
NanoDocePhase 11 trial
Active Trials
NCT04260360WithdrawnEst. Oct 2022
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
NintedanibPhase 1Small Molecule1 trial
Active Trials
NCT02835833Completed21Est. Jun 2018
Ipsen
IpsenChina - Tianjin
4 programs
CabozantinibN/ASmall Molecule1 trial
CabozantinibN/ASmall Molecule1 trial
Data collectionN/A1 trial
Post-marketing Surveillance on the Safety of CabometyxTM in Korean PatientsN/A1 trial
Active Trials
NCT04637204Completed1,540Est. Dec 2020
NCT04510688Completed275Est. Jun 2022
NCT03419572Completed689Est. May 2022
+1 more trials
CP
Chugai PharmaJapan - Tokyo
1 program
PD-L1 Expression in Japanese Renal Cell Carcinoma PatientsN/A1 trial
Active Trials
NCT03748901Completed830Est. Jul 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
PfizerBevacizumab
PfizerBevacizumab
Heidelberg PharmaIodine
EisaiLenvatinib
PfizerBevacizumab
PfizerBevacizumab
Heidelberg Pharma124-Iodine-cG250
Bayersorafenib
Active BiotechABR-217620/naptumomab estafenatox
Arcus BiosciencesCasdatifan
ModernaIntismeran autogene
PfizerBevacizumab
PfizerAxitinib plus Toripalimab
Bristol Myers SquibbNeoadjuvant nivolumab
EisaiPembrolizumab

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 7,109 patients across 50 trials

NCT05253651PfizerBevacizumab

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Start: Oct 2022Est. completion: Jul 2029400 patients
Phase 3Recruiting
NCT04325698PfizerBevacizumab

A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC

Start: Jun 2020Est. completion: May 20218 patients
Phase 3Terminated
NCT01762592Heidelberg PharmaIodine

REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT

Start: Dec 2017Est. completion: Dec 20190
Phase 3Withdrawn
NCT02811861EisaiLenvatinib

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

Start: Oct 2016Est. completion: Mar 20271,069 patients
Phase 3Active Not Recruiting
NCT02364999PfizerBevacizumab

A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC

Start: Apr 2015Est. completion: Dec 2017719 patients
Phase 3Completed
NCT00631371PfizerBevacizumab

Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects

Start: Apr 2008Est. completion: Apr 2015791 patients
Phase 3Completed
NCT00606632Heidelberg Pharma124-Iodine-cG250

Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody

Start: Mar 2008Est. completion: Dec 2009226 patients
Phase 3Completed
NCT00478114Bayersorafenib

Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)

Start: May 2007Est. completion: Mar 201015 patients
Phase 3Completed
NCT00420888Active BiotechABR-217620/naptumomab estafenatox

ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma

Start: Jan 2007Est. completion: Jan 2013
Phase 2/3Completed
NCT07397611Arcus BiosciencesCasdatifan

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Start: Jul 2026Est. completion: Sep 2029
Phase 2Not Yet Recruiting
NCT06307431ModernaIntismeran autogene

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

Start: Apr 2024Est. completion: Jun 2032272 patients
Phase 2Active Not Recruiting
NCT06106308PfizerBevacizumab

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Start: Feb 2024Est. completion: Jan 2027113 patients
Phase 2Active Not Recruiting
NCT05738694PfizerAxitinib plus Toripalimab

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Start: Apr 2023Est. completion: Dec 2027298 patients
Phase 2Recruiting
NCT05148546Bristol Myers SquibbNeoadjuvant nivolumab

Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer

Start: Apr 2022Est. completion: Apr 202969 patients
Phase 2Active Not Recruiting
NCT04704219EisaiPembrolizumab

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

Start: Feb 2021Est. completion: Oct 2025160 patients
Phase 2Completed
NCT03173560Eisailenvatinib

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

Start: Aug 2017Est. completion: Jun 2024343 patients
Phase 2Completed
NCT03029780Bristol Myers SquibbOpdivo

An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma

Start: Feb 2017Est. completion: Jun 2021104 patients
Phase 2Completed
NCT02763761Bristol Myers SquibbInfliximab + Prednisone

An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

Start: Aug 2016Est. completion: Mar 20170
Phase 2Withdrawn
NCT02306954Providence TherapeuticsHigh Dose IL-2

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

Start: Dec 2014Est. completion: Dec 2026
Phase 2Active Not Recruiting
NCT02072044Chia Tai TianQing Pharmaceutical GroupAnlotinib

Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy

Start: Dec 2013Est. completion: Dec 2017
Phase 2Unknown
NCT02821559PfizerBevacizumab

Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer

Start: Jul 201237 patients
Phase 2Completed
NCT01490866PfizerBevacizumab

A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)

Start: Jan 2012Est. completion: Jul 201570 patients
Phase 2Completed
NCT01062178Lantheus Medical ImagingDefinity

Efficacy of Ultrasound Contrast Agent to Assess Renal Masses

Start: Oct 2009Est. completion: Dec 2012
Phase 2Completed
NCT01022918PfizerBevacizumab

Evaluation of the Irinotecan/Bevacizumab Association for Naive Unresectable Glioblastoma

Start: Jan 2009Est. completion: Jan 2011134 patients
Phase 2Completed
NCT00800917PfizerBevacizumab

A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme

Start: Nov 2008Est. completion: Feb 201012 patients
Phase 2Completed
NCT00561912EisaiDecitabine

Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma

Start: Oct 2007Est. completion: Nov 20092 patients
Phase 2Terminated
NCT00480389BayerSorafenib

Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal

Start: May 2007Est. completion: Mar 201319 patients
Phase 2Completed
NCT00523159Immatics BiotechnologiesEndoxana, IMA901, Leukine

IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease

Start: May 2007Est. completion: Aug 200968 patients
Phase 2Completed
NCT00353301GenentechErlotinib hydrochloride

Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma

Start: Jul 2006Est. completion: Mar 201225 patients
Phase 2Completed
NCT00323011PfizerBevacizumab

FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer

Start: May 2006Est. completion: Nov 20075 patients
Phase 2Terminated
NCT00106054PfizerBevacizumab

Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases

Start: Jan 2006Est. completion: Sep 20062 patients
Phase 2Terminated
NCT00176280BayerLeukine

Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma

Start: Sep 20050
Phase 2Withdrawn
NCT00354978PfizerBevacizumab

Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients

Start: Jan 2005Est. completion: Mar 201149 patients
Phase 2Completed
NCT00100685AbbottVolociximab

Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)

Start: Jan 2005Est. completion: Dec 200748 patients
Phase 2Terminated
NCT00036036AstellasCP-461

Study of CP-461 in Patients With Advanced Renal Cell Cancer

Start: Jul 2001Est. completion: Jul 200314 patients
Phase 2Completed
NCT00625755SanofiElectrofusion DC vaccine

A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma

Start: Dec 2002Est. completion: Feb 200840 patients
Phase 1/2Completed
NCT07195682Bristol Myers SquibbBMS-986506

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Start: Jan 2026Est. completion: Apr 2031125 patients
Phase 1Recruiting
NCT07318805PfizerBevacizumab

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Start: Dec 2025Est. completion: Apr 2030260 patients
Phase 1Recruiting
NCT06447662PfizerBevacizumab

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Start: Jun 2024Est. completion: Sep 2028330 patients
Phase 1Recruiting
NCT06010875Precision BioSciencesCD70 CAR-T cells

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Start: Nov 2023Est. completion: Sep 202648 patients
Phase 1Recruiting
NCT06131840PfizerBevacizumab

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Start: Nov 2023Est. completion: Sep 2030914 patients
Phase 1Recruiting
NCT05789069HiFiBiO TherapeuticsHFB200603

A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Start: May 2023Est. completion: Dec 2025
Phase 1Active Not Recruiting
NCT04126044PfizerBevacizumab

A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS

Start: Jan 2021Est. completion: Jul 20210
Phase 1Withdrawn
NCT04707248Daiichi SankyoDS-6000a

A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

Start: Dec 2020Est. completion: Jun 2026179 patients
Phase 1Active Not Recruiting
NCT04438083CRISPR TherapeuticsCTX130

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

Start: Jun 2020Est. completion: Oct 202419 patients
Phase 1Terminated
NCT04260360Biotest PharmaceuticalsNanoDoce

Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma

Start: Apr 2020Est. completion: Oct 2022
Phase 1Withdrawn
NCT03324373EisaiLenvatinib

Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)

Start: Mar 2019Est. completion: Aug 202411 patients
Phase 1Completed
NCT02835833Boehringer IngelheimNintedanib

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

Start: Jun 2016Est. completion: Jun 201821 patients
Phase 1Completed
NCT02133742PfizerAxitinib

A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer

Start: Sep 2014Est. completion: Jul 201952 patients
Phase 1Completed
NCT02216890PfizerSGN-CD70A

Safety Study of SGN-CD70A in Cancer Patients

Start: Aug 2014Est. completion: Feb 201738 patients
Phase 1Completed

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
1h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
3h ago

Executive Director, I.T.- Head of Security Architecture, Engineering, and Delivery

Gilead Sciences
United States - California - Foster City
17h ago
$281K - $364K/yr

Sr Research Associate, Analytical Operations

Gilead Sciences
United States - California - Oceanside
17h ago
$86K - $112K/yr

Associate Director, Insights & Analytics Platform Technology Lead

Gilead Sciences
United States - California - Foster City
17h ago
$196K - $253K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs — potential near-term approvals
7 actively recruiting trials targeting 7,109 patients
28 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)